Linked Life Data

2127987

Source:http://linkedlifedata.com/resource/pubmed/id/2127987

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5
pubmed:dateCreated
1991-5-6
pubmed:abstractText
CNS availability of compounds with neurological or nonneurological indication, CNS bioequivalence of different compounds/formulations, and CNS drug interactions can be estimated reliably in man by application of quantitative EEG procedures in controlled experimental conditions. Mapping approaches increase the visibility of drug-mediated EEG modifications with limited or selective scalp distribution, thus increasing the control on individual variability and allowing the study of interactions between drugs effect and background EEG pattern, including EEG concomitants of pathological substrata. Correlative structural/functional studies (EEG, CT, NMR, rCBF) are made possible. The pharmaco-EEG potentialities are therefore incremented in the study of compounds of new generation and in nontraditional clinical/therapeutic conditions (cognitive impairments, brain aging, dementia, epilepsies).
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:status
MEDLINE
pubmed:month
Oct
pubmed:issn
0001-6276
pubmed:author
pubmed:issnType
Print
pubmed:volume
12
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
389-409
pubmed:dateRevised
2004-11-17
pubmed:meshHeading
pubmed:year
1990
pubmed:articleTitle
Quantitative EEG in human neuropharmacology. Rationale, history, and recent developments.
pubmed:affiliation
Center for Neuropsychoactive Drugs, University, Genova.
pubmed:publicationType
Journal Article, Review